Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11521800 | 0.61 | GAA (0.32) | GAAMAPT | |
| SCHEMBL19679 | 0.61 | — | — | |
| SCHEMBL265188 | 0.60 | MAOB (0.59) | — | |
| SCHEMBL31337867 | 0.60 | MAOB (0.59) | — | |
| SCHEMBL8535074 | 0.58 | GAA (0.37) | GAAMAPT | |
| SCHEMBL29415525 | 0.58 | GAA (0.48) | GAAMAPT | |
| SCHEMBL34295 | 0.58 | GAA (0.48) | GAAMAPT | |
| SCHEMBL160159 | 0.58 | GAA (0.38) | GAAMAPT | |
| SCHEMBL2507520 | 0.57 | GAA (0.36) | GAAMAPT | |
| Potassium SCHEMBL9683518 | 0.57 | GAA (0.46) | GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103524432-B | One prepares the method for 2,3-dihydroquinazoline-4 (3H)-one analog derivative | 贵州大学 | 2016-06-08 | — | — | CN | claimed |
| EP-2908817-A1 | 2,3-DIHYDROQUINAZOLIN-4(1 H)-ONE DERIVATIVES FOR USE IN THE TREATMENT OF VIRAL INFECTIONS | Commissariat à l'Énergie Atomique et aux Énergies Alternatives (FR) | 2015-08-26 | — | — | EP | claimed |
| WO-2014060588-A1 | 2,3-DIHYDROQUINAZOLIN-4(1 H)-ONE DERIVATIVES FOR USE IN THE TREATMENT OF VIRAL INFECTIONS | COMMISSARIAT A L'ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES (FR) | 2014-04-24 | — | — | WO | claimed |
| CN-103524432-A | Method for preparing 2,3-dihydroquinazoline-4(3H)-ketone derivatives | UNIV GUIZHOU | 2014-01-22 | — | — | CN | claimed |
| EP-2350030-A1 | ISOXAZOLE/ISOXAZOLINE/COMBRETASTATIN LINKED DIHYDROQUINAZOLINONE HYBRIDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | Council Of Scientific & Industrial Research (IN) | 2011-08-03 | — | — | EP | claimed |
| CN-101845021-A | Quinazoline ketones alkaloid and preparation method and application thereof | OCEAN UNIV CHINA | 2010-09-29 | — | — | CN | claimed |
| WO-2010058417-A1 | ISOXAZOLE/ISOXAZOLINE/COMBRETASTATIN LINKED DIHYDROQUINAZOLINONE HYBRIDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2010-05-27 | — | — | WO | claimed |
| CN-104557737-B | A kind of synthetic method of 2 aryl substituted quinazoline class medicine intermediates | 王文明 | 2016-12-14 | — | — | CN | disclosed |
| CN-106083741-A | 2 sulfur are for quinazolinedione derivatives | 南京中医药大学 | 2016-11-09 | — | — | CN | disclosed |
| CN-103524432-B | One prepares the method for 2,3-dihydroquinazoline-4 (3H)-one analog derivative | 贵州大学 | 2016-06-08 | — | — | CN | disclosed |
| CN-104744380-A | Method for preparing 2,3-dihydroquinazoline-4(1H)-one and derivative thereof | UNIV ANHUI TECHNOLOGY | 2015-07-01 | — | — | CN | disclosed |
| CN-104557737-A | Method for synthesizing 2-aryl-substituted quinazoline medical intermediate | MA LIANGJUN | 2015-04-29 | — | — | CN | disclosed |
| CN-104356076-A | Synthesis method for substituted 2, 3-dihydro-4(1H)-quinazolinone compound | UNIV BOHAI | 2015-02-18 | — | — | CN | disclosed |
| CN-1665804-A | 4, 4-disubstituted piperidine derivatives having CCR3 antagonism | TEIJIN LTD (JP) | 2005-09-07 | — | — | CN | disclosed |
| EP-1507776-A1 | 2-OXO-1,3,4-TRIHYDROQUINAZOLINYL DERIVATIVES FOR THE TREATMENT OF CELL PROLIFERATION-RELATED DISORDERS | Amgen Inc. (US) | 2005-02-23 | — | — | EP | disclosed |
| CN-1578768-A | Anthranilamides and pharmaceutical use thereof | NOVARTIS AG (CH) | 2005-02-09 | — | — | CN | disclosed |
| US-20030232846-A1 | Caspase inhibitors and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED | 2003-12-18 | — | — | US | disclosed |
| WO-2003101985-A1 | 2-OXO-1,3,4-TRIHYDROQUINAZOLINYL DERIVATIVES FOR THE TREATMENT OF CELL PROLIFERATION-RELATED DISORDERS | AMGEN INC. (US) | 2003-12-11 | — | — | WO | disclosed |
| EP-1244626-A2 | CASPASE INHIBITORS AND USES THEREOF | Vertex Pharmaceuticals Incorporated (US) | 2002-10-02 | — | — | EP | disclosed |
| WO-2001042216-A2 | CASPASE INHIBITORS AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2001-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232846-A1 | Caspase inhibitors and uses thereof | CASP1, CASP3, CASP2 | GAA 2029/4885MAPT 3562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.